mRNA Technology

Vaccine Development Vaccine Technology Drug Development Clinical Trials Research and Development Therapeutics Vaccine Production Lipid Nanoparticles Cancer Treatment Cancer Research Vaccine Innovation Innovations Personalized Medicine Cancer Therapy mRNA-1083 Cancer Vaccines Artificial Intelligence Drug Delivery Systems Pharmaceutical Technology Vaccine Delivery Cancer Treatment Innovations Healthcare Innovations Therapeutic Development Vaccines Vaccine Delivery Systems Lipid Nanoparticle Delivery Cancer Therapies Applications Immunotherapy

46 ARTICLES

2mo ago

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

The authorization brings the first U.S.‑licensed mRNA seasonal flu vaccine but its public rollout is uncertain because the CDC advisory panel cannot meet to set formal recommendations.

3 ARTICLES

3mo ago

Moderna Posts Q2 Revenue Beat as Norovirus Trial Misses Interim Goal

14 ARTICLES

4mo ago

FDA Advisers Unanimously Back Moderna’s mRNA Flu Vaccine

7 ARTICLES

5mo ago

NewLimit Raises $435 Million to Advance First Human Trial for Liver Rejuvenation

3 ARTICLES

5mo ago

BioNTech Founders to Exit This Year to Launch New mRNA Company as Stock Slumps on Weak Outlook

15 ARTICLES

8mo ago

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

3 ARTICLES

8mo ago

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

6 ARTICLES

9mo ago

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

5 ARTICLES

10mo ago

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

7 ARTICLES

last yr.

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

9 ARTICLES

last yr.

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

8 ARTICLES

last yr.

US Cuts $500 Million in mRNA Vaccine Research Funding

7 ARTICLES

last yr.

Membrane-Bound mRNA HIV Vaccine Elicits Neutralizing Antibodies in 80% of Participants

5 ARTICLES

last yr.

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

4 ARTICLES

last yr.

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

mRNA Technology

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

Moderna Posts Q2 Revenue Beat as Norovirus Trial Misses Interim Goal

FDA Advisers Unanimously Back Moderna’s mRNA Flu Vaccine

NewLimit Raises $435 Million to Advance First Human Trial for Liver Rejuvenation

Lilly Acquires Engage Biologics for Up to $202 Million

Moderna Jumps on Hantavirus Cruise-Ship Cluster as U.S. Repatriates 17 Citizens

Moderna Beats Q1 Forecast as Overseas COVID Shot Sales Rebound

Moderna Begins Phase III Trial of mRNA Bird Flu Vaccine in UK and US

BioNTech Founders to Exit This Year to Launch New mRNA Company as Stock Slumps on Weak Outlook

Moderna Reaches Up to $2.25 Billion LNP Patent Settlement, Pays $950 Million Upfront

Never miss stories about

mRNA Technology

FDA to Review Moderna’s Flu Shot as Shares Rally on Earnings Beat

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

CEPI Puts Up to $54.3 Million Behind Moderna’s H5 mRNA Bird Flu Vaccine for Phase 3

Moderna Scraps CMV Vaccine Program After Phase 3 Failure

HHS Axes $500 Million in BARDA mRNA Vaccine Projects, Drawing Intensifying Warnings

US Cuts $500 Million in mRNA Vaccine Research Funding

Membrane-Bound mRNA HIV Vaccine Elicits Neutralizing Antibodies in 80% of Participants

Moderna’s mRNA-1010 Flu Vaccine Shows Superior Efficacy in Phase 3 Trial

BioNTech to Acquire CureVac for $1.25 Billion to Drive mRNA Cancer Therapy

Never miss stories about

mRNA Technology